Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

FcγRIIIa-dependent IFN-γ release in whole blood assay is predictive of therapeutic IgG1 antibodies safety.

Alakhras NS, Qiu J, Rocha GV, Witcher DR, Koester A, You J, Schaer DA, Holmgaard RB, Driscoll K, Willy JA, Malherbe LP.

MAbs. 2018 Aug/Sep;10(6):913-921. doi: 10.1080/19420862.2018.1474996. Epub 2018 Jul 26.

2.

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.

Holmgaard RB, Schaer DA, Li Y, Castaneda SP, Murphy MY, Xu X, Inigo I, Dobkin J, Manro JR, Iversen PW, Surguladze D, Hall GE, Novosiadly RD, Benhadji KA, Plowman GD, Kalos M, Driscoll KE.

J Immunother Cancer. 2018 Jun 4;6(1):47. doi: 10.1186/s40425-018-0356-4.

3.

Preclinical assessment of galunisertib (LY2157299 monohydrate), a first-in-class transforming growth factor-β receptor type I inhibitor.

Yingling JM, McMillen WT, Yan L, Huang H, Sawyer JS, Graff J, Clawson DK, Britt KS, Anderson BD, Beight DW, Desaiah D, Lahn MM, Benhadji KA, Lallena MJ, Holmgaard RB, Xu X, Zhang F, Manro JR, Iversen PW, Iyer CV, Brekken RA, Kalos MD, Driscoll KE.

Oncotarget. 2017 Dec 31;9(6):6659-6677. doi: 10.18632/oncotarget.23795. eCollection 2018 Jan 23.

4.

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.

Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP.

Nat Commun. 2017 Feb 13;8:14340. doi: 10.1038/ncomms14340.

5.

Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.

Holmgaard RB, Brachfeld A, Gasmi B, Jones DR, Mattar M, Doman T, Murphy M, Schaer D, Wolchok JD, Merghoub T.

Oncoimmunology. 2016 Apr 25;5(7):e1151595. doi: 10.1080/2162402X.2016.1151595. eCollection 2016 Jul.

6.

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.

Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD.

EBioMedicine. 2016 Apr;6:50-58. doi: 10.1016/j.ebiom.2016.02.024. Epub 2016 Feb 13.

7.

The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment.

Sharma MD, Shinde R, McGaha TL, Huang L, Holmgaard RB, Wolchok JD, Mautino MR, Celis E, Sharpe AH, Francisco LM, Powell JD, Yagita H, Mellor AL, Blazar BR, Munn DH.

Sci Adv. 2015 Nov 6;1(10):e1500845. doi: 10.1126/sciadv.1500845. eCollection 2015 Nov.

8.

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.

Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD.

Cell Rep. 2015 Oct 13;13(2):412-24. doi: 10.1016/j.celrep.2015.08.077. Epub 2015 Sep 24.

9.

The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, Merghoub T.

Adv Cancer Res. 2015;128:1-68. doi: 10.1016/bs.acr.2015.04.010. Epub 2015 Jun 9. Review.

PMID:
26216629
10.

Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP.

Sci Transl Med. 2014 Mar 5;6(226):226ra32. doi: 10.1126/scitranslmed.3008095.

11.

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP.

J Exp Med. 2013 Jul 1;210(7):1389-402. doi: 10.1084/jem.20130066. Epub 2013 Jun 10.

12.

Association of a functional Indoleamine 2,3-dioxygenase 2 genotype with specific immune responses.

Køllgaard T, Klausen TW, Idorn M, Holmgaard RB, Straten PT, Andersen MH.

Oncoimmunology. 2012 Jul 1;1(4):441-447.

Supplemental Content

Loading ...
Support Center